Earnings
TG Therapeutics Sees Self-Administered BRIUMVI Potentially More Than Doubling Its Peak-Sales Opportunity
Management plans an auto-injector launch in 2028, while raising its U.S. product-sales forecast to $915–920 million.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Management plans an auto-injector launch in 2028, while raising its U.S. product-sales forecast to $915–920 million.
Markets
The drug's slower launch prompted the cut, but Ionis kept its overall revenue outlook at $875–900 million.
Markets
ANKTIVA product revenue grew 53%, while research spending rose and the company reported success in a bladder-cancer trial.
Earnings
Management says core patents protect TONMYA into 2034 and describes successor research as small beside its depression trial.
Earnings
Power, refining and mining helped drive industrial growth, while management raised its full-year sales outlook to approximately 7%.
Earnings
Diagnostic-partner revenue fell to $1.2 million as recurring testing sales failed to offset fewer instrument placements.
Earnings
Management defended its trial size and potential approval timing as analysts pressed on the evidence needed to compete.
Earnings
Manufacturing delays and longer deliveries hurt orders at Dreams, while higher transportation costs also weighed on the outlook.
Earnings
Management expects holiday schedules and fewer new patient starts to slow the fourth quarter, even as its treatment network expands.
Earnings
Existing grocery warehouses would supply shops at night, while a stronger tenge prompted a cut to merchandise-sales growth guidance.
Earnings
Higher-dose patients maintained arthritis responses, but FDA discussions will determine the next trial's design.
Earnings
The bedding company's $2.90 adjusted earnings outlook includes a partial-year contribution from Leggett & Platt.